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LETTERS TO THE EDITOR 
Homografl replacement of the mitral valve 
To the Editor: 
In the February 1996 issue of the Journal, Acar and 
collaborators published an article titled: "Homograft 
Replacement of the Mitral Valve: Graft Selection, 
Technique of Implantation, and Results in Forty-three 
Patients" (1996;111:367-80). We congratulate the au- 
thors for their interest in extending the present limita- 
tions of mitral valve repair by the use of a mitral valve 
homograft. 
We wish to make the following corrections: 
In reference to Morea's article 1 (reference 19), the 
Biocor porcine stentless mitral valve was developed and is 
manufactured byBiocor Inddstria e Pesquisas Ltda from 
Belo H0fizonte, Brazil. 
The Biocor porcine stentless mitral valve is made 
entirely of biologic material, and new chordal insertions 
including athin slice of papillary muscle are "sandwiched" 
between xenograft pericardial patches, thereby securing 
the chordal insertion firmly. 
Morea's article clearly states that healing between 
pericardial tissue and papillary muscles was satisfac- 
tory. 
Occasional chordal rupture was always due to previ- 
ous endocarditis. We have used the Biocor mitral 
stentless valve in more than 120 patients with the 
longest follow-up being 4 years. Although there is a 
definite learning curve related to use of the new valve 
and new technique, current excellent results makes this 
valve our valve of choice for the mitral position in our 
institute, especially when patient criteria are met as 
stated in published papers. 2-1° 
Valve mismatch and chordal malalignment must be 
prevented to avoid complications such as leaflet pro- 
lapse, valve insufficiency, and leaflet tear. The use of a 
mitral ring will ameliorate any valve dysfunction when 
there is minor mismatch and malalignment. If one 
wants to be consistent in using only biologic tissues, it is 
advisable to use a pericardial mitral ring to correct mild 
mismatches. 
Papillary muscle structure is less resistant than suture 
material. Therefore the use of pledger-supported sutures 
(preferably of pericardial tissue) may prevent muscle 
laceration. 
In none of our patients was the use of pledget-sup- 
ported sutures responsible for any complications. It must 
be stressed that accurate technique, fine needles, avoid- 
ance of more than one needle ntrance, and avoidance of 
excessive traction on the biologic tissue are vital. Failure 
to do so is a common cause leading to unfavorable r sults. 
With experience, the aforementioned complications can 
be prevented. 
We too believe in the importance of preserving annu- 
loventricular continuity in mitral valve surgery. Although 
the use of new devices and technique does have a clear 
learning curve, quality of life, left ventricular remodeling, 
1678 
and longer patient survival may be achieved through these 
new techniques. 
Prof. Mario Vrandecic 
Prof. Bayard Gontijo 
Prof. Fernando Fantini 
Biocor Institute 
Caixa Postal 106 
Belo Horizonte, Cep: 30161-970, Brazil 
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